Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Post by Biofinderon May 13, 2018 11:08pm
432 Views
Post# 28024859

Some Interesting Pharmaceutical Industry Fun Facts

Some Interesting Pharmaceutical Industry Fun FactsPrometic will soon be chasing a US$58+ billion dollar WW market with their two drugs, Ryplazim and 4050, and has a chance to take its place among the industry leaders.
 
Ryplazim has no current competition and will own the plasminogen WW market. I know of no other pharmaceutical company currently pursuing the plasminogen market.
 
4050 has the chance to become the market’s standard/drug of choice as the only currently know drug to reverse fibrosis in five organs.
 
Below are listed the revenue for some of the largest pharmaceuticals (2016 data):
 
  • Johnson & Johnson: US$71.89 billion 
  • Pfizer: US$52.82 billion 
  • Roche: US$50.11 billion
  • Novartis: US$48.52 billion 
  • Merck & Co: US$39.8 billion 
  • Sanofi: US$36.57 billion 
  • GlaxoSmithKline (GSK): US$34.79 billion 
  • Gilead: US$30.39 billion 
 
How big of a slice of the US$58+ billion WW market will Prometic be able to capture? Only time will tell. But 2020 appears to be when it may finally all come together for Prometic.

Bullboard Posts